Videos

Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.

Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.

Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.

Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.

Panelists discuss how community practices establish protocols and processes for ongoing monitoring and management of potential long-term complications or adverse events from bispecific therapy.

Panelists discuss how academic centers approach the initial consultation and evaluation process for patients referred for bispecific therapy from community practices.

Panelists discuss how transitioning patients with multiple myeloma from community to academic settings faces challenges including communication gaps, differences in treatment approaches, patient reluctance, and logistical hurdles.

Panelists discuss recent updates in the management of relapsed/refractory multiple myeloma, focusing on key studies such as MonumenTAL-2 for talquetamab, long-term follow-up data from the phase 1/2 MajesTEC-1 for teclistamab, and findings from MagnetisMM-3 regarding elranatamab.

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

Panelists discuss how community practices implement protocols and processes to monitor and manage potential long-term complications or adverse events associated with bispecific therapy, focusing on patient follow-up, adverse event reporting, and ongoing risk assessment.

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

Panelists discuss how data from the long-term CARTITUDE-4 study update in multiple myeloma (MM) highlight the sustained efficacy and safety of ciltacabtagene autoleucel, reinforcing its role as a promising treatment option for patients with lenalidomide-refractory disease.

Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.

Shannon N. Westin, MD, discusses chemotherapy options for endometrial cancer as well as the results of her phase 3 DUO-E trial.

Shannon N. Westin, MD, discusses how patient considerations for immunotherapy treatment involve evaluating individual health profiles, potential adverse effects, and the importance of personalized approaches to enhance treatment efficacy and patient quality of life.

Shannon N. Westin, MD, discusses how neoadjuvant treatment considerations for endometrial cancer can improve surgical outcomes and patient prognosis through the use of personalized, multidisciplinary approaches tailored to individual tumor characteristics.

Shannon N. Westin, MD, discusses the molecular classification of endometrial cancer.

Shannon N. Westin, MD, provides an overview of endometrial cancer to the Oncology Brothers.

The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.

Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.

Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.

The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.

Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.

Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.

Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.

Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.

Panelists discuss other adverse events associated with amivantamab and lazertinib beyond infusion-related reactions.

Panelists discuss how minimal residual disease (MRD) detection in colorectal cancer (CRC) is improving postsurgical treatment decision-making and enabling more effective monitoring of patient outcomes.

A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.

Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.